Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Treatment of AD/HD HasReached a Stalemate: Prof. Tanaka
April 6, 2009
- 1st Seminar to Promote Use of Generics Held
April 6, 2009
- JSHP Concerned about Exposure of Pharmacists to Anticancer Drugs
April 6, 2009
- Korosho's Survey Confirms Low Generic Substitution Rate
April 6, 2009
- Increases in People's Financial Burden Are Inevitable: MOF
April 6, 2009
- 78.6% of Pharmacies Obtain Premium for Dispensing Generics
April 6, 2009
- Awareness Rate for CKD only 10%: Healthclick
April 6, 2009
- Daiichi Sankyo Sues 13 Companies for Levofloxacin Patent Violation
April 6, 2009
- JSMO Aims at Health Insurance Coverage of KRAS Gene Testing
April 6, 2009
- Many Patients Hesitate to Request Generic Substitution
April 6, 2009
- Synergism with Millennium to Drive Takeda's Business in Oncology
April 6, 2009
- 12 Drugs and 5 APIs Priced
April 6, 2009
- Falsification of Data Found on World's 1st Recombinant Human Albumin
April 6, 2009
- REGULATORY NEWS IN BRIEF
April 6, 2009
- LDP's Research Commission Calls For More Investment in Pharma R&D
April 6, 2009
- UGT1A1 Gene Polymorphism Testing Reagent from Sekisui Medical
April 6, 2009
- R&D NEWS IN BRIEF
April 6, 2009
- Meiji Seika Licenses Drug for Schizophrenia from ACADIA
April 6, 2009
- 7th JSMO Annual Meeting
April 6, 2009
- Eli Lilly Japan: Sales Up 2% to ¥91,773 Mil.
April 6, 2009
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…